Functional and antigenic domains of the matrix (M1) protein of influenza A virus.

PubWeight™: 1.98‹?› | Rank: Top 2%

🔗 View Article (PMC 253942)

Published in J Virol on February 01, 1987

Authors

Z P Ye, R Pal, J W Fox, R R Wagner

Articles citing this

Virus maturation by budding. Microbiol Mol Biol Rev (1998) 3.78

Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J Virol (1991) 3.29

Influenza A virus NS2 protein mediates vRNP nuclear export through NES-independent interaction with hCRM1. EMBO J (2000) 2.54

Effect of M1 protein and low pH on nuclear transport of influenza virus ribonucleoproteins. J Virol (1996) 2.08

Nuclear trafficking of influenza virus ribonuleoproteins in heterokaryons. J Virol (1996) 2.01

Association of influenza virus matrix protein with ribonucleoproteins. J Virol (1999) 1.95

Cell-free assembly of the herpes simplex virus capsid. J Virol (1994) 1.90

Increased virulence of a mouse-adapted variant of influenza A/FM/1/47 virus is controlled by mutations in genome segments 4, 5, 7, and 8. J Virol (1990) 1.84

Identification of the domains of the influenza A virus M1 matrix protein required for NP binding, oligomerization and incorporation into virions. J Gen Virol (2007) 1.83

The influenza virus variant A/FM/1/47-MA possesses single amino acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol (1994) 1.81

Alterations to influenza virus hemagglutinin cytoplasmic tail modulate virus infectivity. J Virol (1992) 1.74

Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol (1989) 1.73

Influenza a viruses with mutations in the m1 helix six domain display a wide variety of morphological phenotypes. J Virol (2005) 1.67

Hyperphosphorylation of mutant influenza virus matrix protein, M1, causes its retention in the nucleus. J Virol (1995) 1.55

RNA-binding properties of influenza A virus matrix protein M1. Nucleic Acids Res (1989) 1.51

Nucleus-targeting domain of the matrix protein (M1) of influenza virus. J Virol (1995) 1.46

Expression of the influenza A virus M2 protein is restricted to apical surfaces of polarized epithelial cells. J Virol (1992) 1.42

Mechanism for inhibition of influenza virus RNA polymerase activity by matrix protein. J Virol (1996) 1.41

Membrane-binding domains and cytopathogenesis of the matrix protein of vesicular stomatitis virus. J Virol (1994) 1.39

The packaging signal of influenza viral RNA molecules. RNA (2001) 1.35

Nuclear retention of M1 protein in a temperature-sensitive mutant of influenza (A/WSN/33) virus does not affect nuclear export of viral ribonucleoproteins. J Virol (1992) 1.31

A nuclear export signal in the matrix protein of Influenza A virus is required for efficient virus replication. J Virol (2012) 1.28

M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol (1989) 1.24

Retracted Basic residues of the helix six domain of influenza virus M1 involved in nuclear translocation of M1 can be replaced by PTAP and YPDL late assembly domain motifs. J Virol (2003) 1.23

Evolution of the M gene of the influenza A virus in different host species: large-scale sequence analysis. Virol J (2009) 1.18

Genomic and protein structural maps of adaptive evolution of human influenza A virus to increased virulence in the mouse. PLoS One (2011) 1.13

A single amino acid change in the C-terminal domain of the matrix protein M1 of influenza B virus confers mouse adaptation and virulence. Virology (2005) 1.09

Restriction of viral replication by mutation of the influenza virus matrix protein. J Virol (2002) 1.03

New aspects of influenza viruses. Clin Microbiol Rev (1992) 0.97

Antiviral activity of influenza virus M1 zinc finger peptides. J Virol (1996) 0.96

Introduction of a temperature-sensitive phenotype into influenza A/WSN/33 virus by altering the basic amino acid domain of influenza virus matrix protein. J Virol (2004) 0.96

F1Fo-ATPase, F-type proton-translocating ATPase, at the plasma membrane is critical for efficient influenza virus budding. Proc Natl Acad Sci U S A (2012) 0.96

In vivo anti-influenza virus activity of a zinc finger peptide. Antimicrob Agents Chemother (1997) 0.93

Matrix protein 1: A comparative in silico study on different strains of influenza A H5N1 Virus. Bioinformation (2006) 0.88

Changes in mumps virus gene sequence associated with variability in neurovirulent phenotype. J Virol (2003) 0.87

Attenuating mutations of the matrix gene of influenza A/WSN/33 virus. J Virol (2005) 0.86

The highly conserved arginine residues at positions 76 through 78 of influenza A virus matrix protein M1 play an important role in viral replication by affecting the intracellular localization of M1. J Virol (2011) 0.84

Interaction of NS2 with AIMP2 facilitates the switch from ubiquitination to SUMOylation of M1 in influenza A virus-infected cells. J Virol (2014) 0.78

Characterization of the antiviral activity for influenza viruses M1 zinc finger peptides. Curr Microbiol (2010) 0.75

Articles cited by this

Protein measurement with the Folin phenol reagent. J Biol Chem (1951) 1743.91

Nucleotide sequences of the mRNA's encoding the vesicular stomatitis virus G and M proteins determined from cDNA clones containing the complete coding regions. J Virol (1981) 7.97

Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell (1985) 6.44

Sequences of mRNAs derived from genome RNA segment 7 of influenza virus: colinear and interrupted mRNAs code for overlapping proteins. Proc Natl Acad Sci U S A (1981) 5.57

Cloning of influenza cDNA ino M13: the sequence of the RNA segment encoding the A/PR/8/34 matrix protein. Nucleic Acids Res (1980) 4.75

The gene structure and replication of influenza virus. Annu Rev Biochem (1983) 4.30

Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol (1979) 3.54

The matrix (M) protein of vesicular stomatitis virus regulates transcription. Cell (1978) 2.81

Antigenic characterization of viruses by monoclonal antibodies. Annu Rev Microbiol (1981) 2.63

The structure of influenza virus. II. A model based on the morphology and composition of subviral particles. Virology (1972) 2.60

Cleavage at aspartyl-prolyl bonds. Methods Enzymol (1977) 2.10

Interaction of wild-type and mutant M protein vesicular stomatitis virus with nucleocapsids in vitro. Biochemistry (1981) 2.06

Influence of membrane (M) protein on influenza A virus virion transcriptase activity in vitro and its susceptibility to rimantadine. J Virol (1980) 1.88

Influenza virus RNA segment 7 has the coding capacity for two polypeptides. Virology (1980) 1.80

Role of matrix protein in assembling the membrane of vesicular stomatitis virus: reconstitution of matrix protein with negatively charged phospholipid vesicles. Biochemistry (1981) 1.71

Insertion of influenza M protein into the viral lipid bilayer and localization of site of insertion. J Virol (1981) 1.65

Incorporation of influenza virus M-protein into liposomes. J Virol (1980) 1.61

The membrane protein of influenza virus: extraction from virus and infected cell with acidic chloroform-methanol. Virology (1973) 1.55

Homology between the glycoproteins of vesicular stomatitis virus and rabies virus. J Virol (1982) 1.55

Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J Virol (1982) 1.54

Antigenic characterization of influenza A virus matrix protein with monoclonal antibodies. J Virol (1984) 1.49

Further observations on the structure of influenza viruses A and C. J Gen Virol (1969) 1.43

In vitro synthesis of triphosphate-initiated N-gene mRNA oligonucleotides is regulated by the matrix protein of vesicular stomatitis virus. J Virol (1982) 1.42

Interaction of influenza M protein with viral lipid and phosphatidylcholine vesicles. J Virol (1980) 1.34

Monoclonal antibodies to the M protein of vesicular stomatitis virus (Indiana serotype) and to a cDNA M gene expression product. J Virol (1985) 1.28

Inhibition of vesicular stomatitis virus transcriptase complex by the virion envelope M protein. Biochem Biophys Res Commun (1979) 1.27

Inhibition of transcription in somatic cells by microinjection of antibodies to chromosomal proteins. Proc Natl Acad Sci U S A (1983) 1.23

Influence of the peripheral matrix protein of vesicular stomatitis virus on the membrane dynamics of mixed phospholipid vesicles: fluorescence studies. Biochemistry (1983) 1.23

Structure of the membrane protein of influenza virus. I. Isolation and characterization of cyanogen bromide cleavage products. J Virol (1979) 1.01

Selective dansylation of M protein within intact influenza virions. J Virol (1982) 0.91

Degradation of intra- and extrahepatic protein by livers of normal and diabetic mice: differential responses to starvation. Proc Natl Acad Sci U S A (1982) 0.90

Interaction of influenza virus proteins with planar bilayer lipid membranes. I. Characterization of their adsorption and incorporation into lipid bilayers. Biochim Biophys Acta (1984) 0.82

Interaction of influenza virus proteins with planar lipid bilayers: a model for virion assembly. Biochem Biophys Res Commun (1981) 0.81

Articles by these authors

Autophosphorylation of the focal adhesion kinase, pp125FAK, directs SH2-dependent binding of pp60src. Mol Cell Biol (1994) 7.53

Comparative sedimentation coefficients of RNA extracted from plaque-forming and defective particles of vesicular stomatitis virus. J Mol Biol (1966) 6.61

Defective T particles of vesicular stomatitis virus. I. Preparation, morphology, and some biologic properties. Virology (1966) 6.37

Dissociation and reconstitution of the transcriptase and template activities of vesicular stomatitis B and T virions. J Virol (1972) 5.93

Classification of rhabdovirus proteins: a proposal. J Virol (1972) 5.54

Proteins of vesicular stomatitis virus: kinetics and cellular sites of synthesis. J Virol (1970) 4.85

Structural proteins of vesicular stomatitis viruses. J Virol (1969) 4.70

Protein composition of the structural components of vesicular stomatitis virus. J Virol (1969) 4.54

Doublecortin, a brain-specific gene mutated in human X-linked lissencephaly and double cortex syndrome, encodes a putative signaling protein. Cell (1998) 4.44

The glycoprotein of vesicular stomatitis virus is the antigen that gives rise to and reacts with neutralizing antibody. J Virol (1972) 4.04

Role of the membrane (M) protein in endogenous inhibition of in vitro transcription by vesicular stomatitis virus. J Virol (1979) 3.54

Defective T particles of vesicular stomatitis virus. II. Biologic role in homologous interference. Virology (1966) 3.49

L protein requirement for in vitro RNA synthesis by vesicular stomatitis virus. J Virol (1973) 3.26

Lipid composition of purified vesicular stomatitis viruses. J Virol (1971) 3.25

Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol (1995) 3.15

Spatial relationships of the proteins of vesicular stomatitis virus: induction of reversible oligomers by cleavable protein cross-linkers and oxidation. J Virol (1977) 2.77

Rabbit macrophage interferons. I. Conditions for biosynthesis by virus-infected and uninfected cells. J Exp Med (1967) 2.46

Carbohydrate composition of vesicular stomatitis virus. J Virol (1971) 2.40

Inhibition of cellular RNA synthesis by nonreplicating vesicular stomatitis virus. Proc Natl Acad Sci U S A (1965) 2.37

Cytoplasmic compartmentalization of the protein and ribonucleic acid species of vesicular stomatitis virus. J Virol (1972) 2.37

Membrane vesiculation function and exocytosis of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1995) 2.23

Protein kinase and phosphoproteins of vesicular stomatitis virus. J Virol (1974) 2.11

Temperature-sensitive mutants of vesicular stomatitis virus: synthesis of virus-specific proteins. J Virol (1971) 2.05

Viral liposomes released from insect cells infected with recombinant baculovirus expressing the matrix protein of vesicular stomatitis virus. J Virol (1993) 2.02

ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun (2000) 1.90

Localization of membrane-associated proteins in vesicular stomatitis virus by use of hydrophobic membrane probes and cross-linking reagents. J Virol (1980) 1.89

Association of vesicular stomatitis virus glycoprotein with virion membrane: characterization of the lipophilic tail fragment. J Virol (1975) 1.88

Ribonucleic acid species of intracellular nucleocapsids and released virions of vesicular stomatitis virus. J Virol (1972) 1.86

Mutations in the X-linked filamin 1 gene cause periventricular nodular heterotopia in males as well as in females. Hum Mol Genet (2001) 1.80

The impact of insecticide-resistance on control of vectors and vector-borne diseases. Bull World Health Organ (1969) 1.80

Mapping regions of the matrix protein of vesicular stomatitis virus which bind to ribonucleocapsids, liposomes, and monoclonal antibodies. J Virol (1986) 1.78

Restitution of infectivity to spikeless vesicular stomatitis virus by solubilized viral components. J Virol (1975) 1.77

Transcription-inhibition and RNA-binding domains of influenza A virus matrix protein mapped with anti-idiotypic antibodies and synthetic peptides. J Virol (1989) 1.73

Role of matrix protein in assembling the membrane of vesicular stomatitis virus: reconstitution of matrix protein with negatively charged phospholipid vesicles. Biochemistry (1981) 1.71

Inhibition of RNA and interferon synthesis in Krebs-2 cells infected with vesicular stomatitis virus. Virology (1966) 1.67

Regulation of viral transcription by the matrix protein of vesicular stomatitis virus probed by monoclonal antibodies and temperature-sensitive mutants. J Virol (1985) 1.66

Sialoglycoprotein of vesicular stomatitis virus: role of the neuraminic acid in infection. J Virol (1974) 1.63

Action of interferon: kinetics and differential effects on viral functions. J Virol (1970) 1.63

The plus-strand leader RNA of VSV inhibits DNA-dependent transcription of adenovirus and SV40 genes in a soluble whole-cell extract. Cell (1982) 1.61

Glycoprotein biosynthesis. Incorporation of glycosyl groups into endogenous acceptors in a Golgi apparatus-rich fraction of liver. J Biol Chem (1971) 1.60

Location of the transcription defect in group I temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1974) 1.58

Mosquito cells infected with vesicular stomatitis virus yield unsialylated virions of low infectivity. J Virol (1975) 1.57

Differential inhibition of host protein synthesis in L cells infected with RNA - temperature-sensitive mutants of vesicular stomatitis virus. J Virol (1976) 1.55

Enveloped viruses as model membrane systems: microviscosity of vesicular stomatitis virus and host cell membranes. Biochemistry (1976) 1.54

Monoclonal antibodies to the glycoprotein of vesicular stomatitis virus: comparative neutralizing activity. J Virol (1982) 1.54

Inhibition of RNA synthesis in mouse myeloma cells infected with vesicular stomatitis virus. J Virol (1978) 1.51

Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods (2000) 1.50

Hemorrhagic metalloproteinases from snake venoms. Pharmacol Ther (1994) 1.50

Serial blood phosphine levels in acute aluminium phosphide poisoning. J Assoc Physicians India (1996) 1.49

Aberrant splicing of a mouse disabled homolog, mdab1, in the scrambler mouse. Neuron (1997) 1.49

Reconstitution into liposomes of the glycoprotein of vesicular stomatitis virus by detergent dialysis. J Biol Chem (1979) 1.48

Characterization of mutations in the gene doublecortin in patients with double cortex syndrome. Ann Neurol (1999) 1.47

Genetic control of insects of public health importance. Bull World Health Organ (1968) 1.47

Nucleus-targeting domain of the matrix protein (M1) of influenza virus. J Virol (1995) 1.46

Primer-mediated enzymatic amplification of cytomegalovirus (CMV) DNA. Application to the early diagnosis of CMV infection in marrow transplant recipients. J Clin Invest (1989) 1.45

Neutralization of tetanus toxin by distinct monoclonal antibodies binding to multiple epitopes on the toxin molecule. Infect Immun (1984) 1.45

Reversible inhibition of interferon synthesis by puromycin: evidence for an interferon-specific messenger RNA. Proc Natl Acad Sci U S A (1965) 1.44

RNA- temperature-sensitive mutants of vesicular stomatitis virus: L-protein thermosensitivity accounts for transcriptase restriction of group I mutants. J Virol (1976) 1.44

Use of UV irradiation to identify the genetic information of vesicular stomatitis virus responsible for shutting off cellular RNA synthesis. J Virol (1979) 1.44

Transcription inhibition and other properties of matrix proteins expressed by M genes cloned from measles viruses and diseased human brain tissue. J Virol (1994) 1.42

Membrane-binding domains and cytopathogenesis of the matrix protein of vesicular stomatitis virus. J Virol (1994) 1.39

Nidogen mediates the formation of ternary complexes of basement membrane components. Kidney Int (1993) 1.37

Structural proteins of two salmonid rhabdoviruses. J Virol (1975) 1.36

Expression of the M gene of vesicular stomatitis virus cloned in various vaccinia virus vectors. J Virol (1988) 1.33

Classification of the New Jersey serotype of vesicular stomatitis virus into two subtypes. J Virol (1978) 1.32

PDZK1, a novel PDZ domain-containing protein up-regulated in carcinomas and mapped to chromosome 1q21, interacts with cMOAT (MRP2), the multidrug resistance-associated protein. Lab Invest (1999) 1.32

Enzymatic transfer of 14C-glucosamine from UDP-N-acetyl-14C-glucosamine to endogenous acceptors in a Golgi apparatus-rich fraction from liver. Biochem Biophys Res Commun (1969) 1.32

Impairment of Gag-specific CD8(+) T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251- and simian-human immunodeficiency virus KU2-infected macaques. J Virol (2001) 1.31

Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol (2011) 1.30

Antigenic and structural analysis of group II allergens (Der f II and Der p II) from house dust mites (Dermatophagoides spp). J Allergy Clin Immunol (1989) 1.30

Monoclonal antibodies to the M protein of vesicular stomatitis virus (Indiana serotype) and to a cDNA M gene expression product. J Virol (1985) 1.28

Characterization of an HIV-1 point mutant blocked in envelope glycoprotein cleavage. Virology (1990) 1.27

cDNA sequences for four snake venom metalloproteinases: structure, classification, and their relationship to mammalian reproductive proteins. Arch Biochem Biophys (1994) 1.27

Inhibition of viral transcriptase by immunoglobulin directed against the nucleocapsid NS protein of vesicular stomatitis virus. J Virol (1975) 1.27

Aspergillus fumigatus allergen I, a major IgE-binding protein, is a member of the mitogillin family of cytotoxins. J Exp Med (1990) 1.25

Effect of arsenic contamination on microbial biomass and its activities in arsenic contaminated soils of Gangetic West Bengal, India. Environ Int (2004) 1.24

Phosphorothioate oligodeoxycytidine interferes with binding of HIV-1 gp120 to CD4. J Acquir Immune Defic Syndr (1991) 1.24

Molecular cloning of a major cockroach (Blattella germanica) allergen, Bla g 2. Sequence homology to the aspartic proteases. J Biol Chem (1995) 1.23

Influence of the peripheral matrix protein of vesicular stomatitis virus on the membrane dynamics of mixed phospholipid vesicles: fluorescence studies. Biochemistry (1983) 1.23

Inhibition of transcription by immunoglobulins directed against the ribonucleoprotein of homotypic and heterotypic vesicular stomatitis viruses. J Virol (1978) 1.22

Inhibition by aurintricarboxylic acid and polyethylene sulfonate of RNA transcription of vesicular stomatitis virus. J Virol (1975) 1.21

Degradation of extracellular matrix proteins by hemorrhagic metalloproteinases. Arch Biochem Biophys (1989) 1.21

Microviscosity of togavirus membranes studied by fluorescence depolarization: influence of envelope proteins and the host cell. J Virol (1976) 1.21

Snake venom metalloendopeptidases: reprolysins. Methods Enzymol (1995) 1.21

Transcription of vesicular stomatitis virus is required to shut off cellular RNA synthesis. J Virol (1979) 1.20

Cellular adsorption function of the sialoglycoprotein of vesicular stomatitis virus and its neuraminic acid. J Virol (1975) 1.19

Mapping of nidogen binding sites for collagen type IV, heparan sulfate proteoglycan, and zinc. J Biol Chem (1993) 1.18

Conformational stability of B cell epitopes on group I and group II Dermatophagoides spp. allergens. Effect of thermal and chemical denaturation on the binding of murine IgG and human IgE antibodies. J Immunol (1990) 1.17

Rabbit macrophage interferons. II. Some physicochemical properties and estimations of molecular weights. J Exp Med (1967) 1.16

A vaccine that prevents pregnancy in women. Proc Natl Acad Sci U S A (1994) 1.16

Use of antiviral-antiferritin hybrid antibody for localization of viral antigen in plasma membrane. J Virol (1971) 1.15

A unique human immunodeficiency virus culture secreting soluble gp160. AIDS Res Hum Retroviruses (1988) 1.15

Mode of action of 5'-linked cholesteryl phosphorothioate oligodeoxynucleotides in inhibiting syncytia formation and infection by HIV-1 and HIV-2 in vitro. Biochemistry (1991) 1.14

Antigenicity, function, and conformation of synthetic oligopeptides corresponding to amino-terminal sequences of wild-type and mutant matrix proteins of vesicular stomatitis virus. J Virol (1988) 1.14

Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d). Proc Natl Acad Sci U S A (1994) 1.14